Onkológia 4/2020

Pharmacological and non-pharmacological possibilities of antracycline and trastuzumab cardiotoxicity risk reduction

Prevention and reduction of anthracycline- and trastuzumab- induced cardiotoxicity is an evolving problem. It is well known that primary prevention of cardiotoxicity can be achieved to some extend by using less cardiotoxic anthracycline analogues, liposomal anthracyclines, non-anthracycline regimens and other approaches. Evidence increasingly shows that the early initiation of cardioprotective agents, such as inhibitors of angiotensin-converting enzyme, blockers of AT1 receptors for angiotensin II (sartans), betablockers and some other drugs during and/or after cancer therapy can be effective in prevention and reduction cardiotoxic complications. Considering the using of these therapeutics in prevention and reduction of clinical cardiotoxicity is also included in the newest ESMO guidelines. Some studies have also suggested that even physical activity can contribute to reduce risk of cardiotoxicity.

Keywords: antracyclines, trastuzumab, cardiotoxicity, prevention, physical activity